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Abstract
Background: Patient-derived organoids (PDO) technology represents an emerging tool for the study of tumor
biology and drug responsiveness, thus being useful to design personalized medicine approaches. Despite several
studies and clinical trials are ongoing using PDO from colorectal and pancreatic cancer, only few research papers
have been published exploiting PDO from breast cancer. Here, we have developed a new protocol to establish
PDO from surgical and biopsy samples. Furthermore, we have set up also the methodologies adopted for culture
and morphological evaluations.
Results: Surgical and core biopsy specimens collected from 33 patients with diagnosis of breast cancer have been
processed using the protocols here described obtaining PDO from cancerous and healthy mammary tissue (when
available) in a quick and easy way with good yields. The more critical aspects influencing the yield were the
characteristic of the tissue of origin (healthy vs tumor tissue) and the amount of material obtained after enzymatic
digestion process. Success rate from healthy samples was about 20,83%, while this percentage was higher in
samples from cancer tissue (i.e. 87,5%). Also the morphological characterization of breast cancer PDO by brightfield
and transmission electron microscopy has been reported.
Conclusions: Despite obtaining some organoids from a surgical or biopsy specimen is not a difficult procedure, the
establishment of a stable organoid line able to grow and replicate, suitable for long-term biobank storage, is not so
obvious. A novel, simple and quick procedure to obtain PDO from surgical and biopsy samples is here proposed to
achieve high success rate .
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Background
An emerging tool in the study of tumor clonal evolution
is represented by patient-derived organoids (PDO) [1].
PDO technology has been firstly employed to investigate
colorectal cancer and to study tumor biology and the
mechanisms of clonal evolution responsible for metasta-
ses formation [1–3]. Besides the possibility to increase
knowledge about the molecular mechanisms related to
tumor evolution, PDO have captured the researcher’s
interest as they represent a useful tool in drug discovery
and screening, paving the way for the development of
novel approaches to personalized medicine [4]. Indeed,
unlike the in vivo models of patient-derived xenograft
(PDX), PDO promise to obtain an ex vivo real-time che-
mosensitivity evaluation for each patient’s tumor, which
could be compatible with the timing of treatment, rapidly
aiding the clinical decision-making [1, 4]. Some preclinical
and clinical trials are ongoing using PDO derived from
colorectal cancer samples like TUMOROID and SENSOR
studies, but evidences with breast cancer are still poor. Re-
cently, PDO have been generated from breast cancer dem-
onstrating their capability to predict drug sensitivity and
tumor clonal evolution, evidencing their huge potential as
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drug screening platform to identify optimal and patient-
tailored treatments [5, 6].
However, at present only few papers describe method-
ologies to obtain breast cancer organoids from clinical
samples. The first one is a work from Whelm group that
describes in detail applications related to organoid tech-
nology [5]. It describes how to obtain PDO from clinical
specimen such as surgical resections, biopsy samples
and ascites effusions. Description of procedures is accur-
ate, but the proposed methodology to separate organoids
from single cells is difficult and time consuming:
repeated centrifugation cycles are necessary to separate
PDO from single cells and to enrich PDO fraction.
Moreover, these protocols are not designed to establish a
PDO culture for biobank purposes and the procedures
of breast cancer organoid maintenance and amplification
are not described in detail [5]. The second work is a
research paper recently published by Clevers and
coworkers that describe the generation of a biobank of
breast cancer PDO, which perfectly recapitulates patients
heterogeneity. The main novelties from this approach are
that (i) the digestion is been performed only with collage-
nase and (ii) for a limited time (1–2 h at 37 °C) and (iii)
there is not a separation between PDO and single cells ob-
tained after the enzymatic digestion [6]. Here, we propose
a new approach to obtain PDO from surgical and biopsy
samples that integrates the most effective procedures from
the two methods proposed by these research groups in a
quick and simple way. Moreover, we display the method-
ologies adopted for PDO culturing and for further
morphological evaluations by immunohistochemistry and
transmission electron microscopy.
Results
The aim of the present study is to develop a simple and
quick method to obtain PDO from surgical and biopsy
specimens of breast cancer patients, to assess the reli-
ability of PDO in recapitulating breast cancer features
for further translational studies. Using the methods de-
scribed in this paper, we have processed surgical and
core biopsy specimens collected from 33 patients treated
at the Breast Unit of ICS Maugeri IRCCS (Pavia, Italy)
from October 2018 to January 2019. All PDO have been
stored in the “Bruno Boerci” biobank established by the
“Bruno Boerci” foundation and hosted by ICS Maugeri
IRCCS. Histological characterization of primary tumors
revealed that 84,84% (28/33) were invasive ductal carcin-
oma (IDC), while 15,15% (5/33) were invasive lobular
carcinoma (ILC) (Fig. 1). Immunohistochemistry assess-
ment of receptors status evidenced that 47,62% (10/33)
were HER2-positive, 85,71% (19/33) were HER2-negative
and only 23,81% (5/33) were triple negative breast can-
cer (TNBC) (Fig. 2).
Establishment of PDO from Surgical Samples
The procedure accurately described in method section
(protocol #1) consists of an overnight digestion at 37 °C
with an enzymatic cocktail of collagenase III and hyaluron-
idase, followed by sequential filtrations on cell strainers
with different porosity (100 and 20 μm) to separate orga-
noids from single cells. In the reference period (from Octo-
ber 2018 to January 2019), we have processed surgical
samples from 24 patients. All included patients were af-
fected by breast cancer at any stage with 79,16% (19/24) of
them classified as patients with IDC, while 20,833% (5/24)
as ILC. For each of them, we have collected and processed
one tumor sample (TB) and one healthy sample from the
most clear margin (HB) as assessed by pathologic gross
examination. About 50,00% (12/24; failed) of specimens
processed from HB has been seeded but has not resulted
in a PDO culture, 25,00% (6/24; unsufficient material) has
not been seeded due the scarce amount of cells and 4,16%
(1/24; bacterial contamination) has been thrown away, due
to bacterial contaminations observed during handling. A
Fig. 1 Graphical representation of distribution of histological
subtypes of tumors from recruited patients
Fig. 2 Graphical representation of distribution of membrane
receptor immunohistochemistry in tumors from recruited patients
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PDO culture has been obtained from HB resection only in
5 of 24 cases, allowing to obtain a success yield of 20,83%
(Fig. 3). Histologic analysis of the sample from which these
5 PDO were derived revealed that 80% (4/5) were classified
as IDC, while 20% (1/5) were ILC (Fig. 4). Moreover, all
the PDO (5/5) obtained from HB samples belonged to
HER2-negative primary lesions by immunohistochemistry.
About TB samples, 12,5% (3/24) of processed specimens
has not resulted in a PDO culture, while none has been ex-
cluded before seeding for lack of PDO in processed sample
or discarded due to bacterial contamination. A PDO cul-
ture has been obtained from TB resection in 21 of 24 cases,
allowing to obtain a success yield of 87,5%. Moreover, 2 of
21 PDO obtained from TB have been frozen (protocol #6)
after a culture period of 2 months and stored in nitrogen
gas for Biobank purposes (Fig. 5). Histologic analysis of TB
primary lesions, which have resulted in PDO culture, re-
vealed that 85,71% (18/21) were IDC, while 14,28% (3/21)
were ILC (Fig. 6). Moreover, 71,42% (15/21) of PDO
obtained from TB samples belonged to primary lesions of
HER2-negative tumors, while 23,81% (7/21) were from
HER2-positive and 4,76% (1/21) Triple Negative Breast
cancer (TNBC). (Fig. 7).
Establishment of PDO from Biopsies
In the same period, we have collected core biopsy sam-
ples from further 9 patients affected by breast cancer
with indication for neoadjuvant chemotherapy (locally
advanced or node-positive disease and/or HER2-positive
or triple-negative subtype). After obtaining the informed
consent, one tissue sample for PDO establishment was
obtained from each patient during standard core biopsy
needed for lesion characterization before starting neoad-
juvant treatment. In 100% (9/9) of processed specimens
we have obtained enough material to be seeded in a well
of 24-wells plate. Histologic analysis revealed that 100%
(9/9) of original biopsies were classified as IDC, with
55,55% (5/9) of them belonging to HER2-positive sub-
type, while 44,44% (4/9) to TNBC (Fig. 8).
Morphological Characterization of PDO
In order to characterize PDO morphology and histology,
we have set up protocols for immunohistochemistry
(ICH) and transmission electron microscopy analysis.
For ICH, the matrigel droplet containing PDO has been
removed from the culture plate with a sterile lifter and
embedded in an agarose matrix before formalin fixation.
Then, paraffin embedding and ICH reactions have been
performed following the procedures used for samples of
clinical routine in order to allow an optimal comparison.
Indeed, the critical feature of the emerging PDO models
is the demonstration of concordance with patient
histology. Results displayed in Fig. 9 evidenced a good
Fig. 3 Graphical representation of results obtained applying
protocol #1 in healthy samples from breast cancer surgical resection
(HB). Specimen processed from HB could have been: obtained
(Obtained), seeded but have not resulted in a PDO culture (Failed),
not been seeded due the scarce amount of cells (Unsufficient
material) or discarded due to bacterial contamination
(bacterial contamination)
Fig. 4 Graphical representation of histological classification of
primary lesions HB that have allowed us to obtain a PDO culture
applying protocol #1
Fig. 5 Graphical representation of results obtained applying
protocol #1 in surgical resection defined by gross examination of
the pathologist as tumor tissue (TB). Specimen processed from TB
could have been: obtained (Obtained), seeded but have not resulted
in a PDO culture (Failed), not been seeded due the scarce amount
of cells (Unsufficient material) or discarded due to bacterial
contamination (bacterial contamination)
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degree of concordance between patient’s tumor and
PDO histology.
Transmission electron microscopy imaging has been
performed following standard preparation of the sample.
In detail, a single drop of PDO embedded in matrigel
has been removed from the culture plate with a sterile
lifter, fixed with buffered glutaraldehyde, dehydrated,
stained and embedded in epon. The sample has been cut
in appropriate slices and analyzed to obtain a mosaic re-
constitution of the entire PDO. This approach allows to
appreciate the structural organization of PDO and the
presence of regions with typical specialization and char-
acteristic features (Figs. 10 and 11).
Discussion
Obtaining some organoids from a surgical or biopsy speci-
men is not a difficult procedure. Indeed, even if we were
not able to see a cellular pellet after the digestion proced-
ure, when we seeded it and we put the Matrigel drop
under light microscope we could identify some PDO in
almost all cases. Despite this, the establishment of a PDO
line able to grow and replicate in culture, as suitable for a
biobank storage, is not so easy. It is necessary to acquire
self-confidence with 3D culture procedures, but also with
each line. Indeed, PDO with compact spherical morph-
ology should be treated in harsh condition to obtain a suc-
cessful shearing. However, a mild mechanical shearing is
sufficient for PDO with grape-like or non-compact
morphology in order to obtain organoids fragmentation.
TryPLE shearing may convert a big PDO in a single cell
suspension in a little amount of time, so it is necessary to
pay maximum attention during this process. In particular,
if the population is highly heterogenous in size, it is very
crucial to take prompt and right decisions about shearing.
Indeed, performing a TryPLE shearing on small PDO may
result in the loss of culture if they split into single cells.
On the other hand, waiting too long before shearing could
risk to let the biggest organoids die. Therefore, an appro-
priate training and observation period are fundamental to
tune cell culture technicians into PDO culture and to ac-
quire the necessary confidence in decision making. In-
deed, since they derive from specific tumors from unique
patients, each PDO differs from another one and requires
to adjust culturing time and shearing procedures. Con-
tinuous and thorough observation of organoids in culture
is key to fine-tune knowledge of PDO features and
morphology to take optimal decisions in order to culture
them in the best way.
Moreover, if the starting material is too little, the
probability to discard the PDO culture after a short
time is very high, being organoids seeded at low density
in a single well not able to grow well. In addition, we
should also consider that different success rates could
be obtained in case we process cancer samples (TB) or
healthy tissue (HB), as expected since cancer cells are
more proliferative than healthy ones. However, obtain-
ing PDO also from healthy tissue is very important for
Fig. 6 Graphical representation of histological classification of
primary lesions that have allowed us to obtain a TB-PDO culture
applying protocol #1
Fig. 7 Graphical representation of membrane receptor classification
of primary lesions TB that have allowed us to obtain a PDO culture
applying protocol #1
Fig. 8 Graphical representation of receptor status of biopsy samples
successfull in PDO culture applying protocol #2
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further applications to allow a comparison with a
control.
These issues coupled with the high costs of Matrigel,
culture medium and supplements have forced us to
hypothesize some check points before seeding the
digested sample. First of all, if the surgical specimen is
from HB tissue and if it results in an invisible pellet after
digestion, it could be better deciding to discard it with-
out trying to establish a PDO culture, since the probabil-
ity to success is too low. Indeed, we have observed that
all the PDO from HB sample that have been discarded,
were first seeded in a single well of 24-wells plate since
the starting material was poor. Moreover, if the PDO
culture grows slowly and it has not been expanded 2
months after initial processing, it becomes reasonable
and more economically advantageous to stop its cultur-
ing. Therefore, the critical point in PDO establishment
is to identify appropriate check points to verify whether
each PDO culture is promising for biobank purposes.
Conclusions
Despite obtaining PDO is not a difficult procedure, the
establishment of an organoid line able to grow and repli-
cate, suitable for a biobank storage, is not so easy. The
present study reports a novel protocol to obtain PDO
from breast cancer, either surgical specimens or biopsy.
The proposed methodology yielded a good success rate
in establishing PDO, which showed histological and bio-
molecular features of concordance with primary tumors,
paving the way for ex vivo characterization of primary
tumors to adequately and timely plan treatments. Given
the promising results obtained with the protocol here
presented, it becomes mandatory to enlarge the patients
cohort to establish breast PDO and perform further
studies.
Methods
Protocol #1: Tissue digestion from breast cancer surgical
specimen
In the reference period, fresh tumor specimens from
surgical resections have been collected from 24 pa-
tients affected by breast cancer at any stage and can-
didated to immediate breast-conserving surgery or
total mastectomy. A written and oral informed con-
sent to participate in the present protocol was ob-
tained from each patient. Tumor specimens obtained
from surgical resection could be stored at 4 °C in
working medium (WM) until processing. Processing
into organoids should be performed in sterile condi-
tions within 48 h from the day of collection. All tissue
Fig. 9 Hematoxylin and eosin staining and immunohistochemistry (ICH) labelling performed on surgical tissue of origin and derived PDO. ICHs
have been performed to label ki67, c-erb B2, E- caderin, estrogen and progesterone receptor. Surgical tissue of origin is represented in large
images, while PDOs are in inserts
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processing was performed in a biosafety cabinet
(hood) using Biosafety Level 2 (BSL2) techniques. The
amount of tissue used for this procedure ranged from
0.17 g to 13.1 g.
1. Transfer the solid tumor tissue in a 6 or 10 cm petri
dish. Assure to keep the tissue moist with PBS.
2. Remove fat tissue and mince tumor sample with
scalpel by criss cross motion.
3. Transfer the minced tissue in a 50 mL tube using a
cell lifter and measure the net weight of the
obtained tissue.
4. Digest the minced tissue in digestion buffer (10 mL/
g of tissue; DMEM-F/12 supplemented with 10 mM
HEPES, 2% BSA, 0.5 μg/ml hydrocortisone, 50 μg/
mL gentamycin) supplemented with Collagenase III
(Wortington #LS004182; 0.2 mg/mL) and with Hy-
aluronidase (Sigma #H3884; 1000 U/mL) for 16 h at
37 °C under shaking (200 rpm).
5. To remove undigested fragments and debris, filter
on sterile 100 μm cell strainer and collect the flow-
through sample (Fig. 12a). This medium mainly
contains PDO, cancer single cells, red blood cells
and fat.
6. Place a sterile 20 μm cell strainer on a new 50 mL
sterile tube and label the tube as single cells
fraction.
7. Discard 100 μm cell strainer and load the medium
collected at passage 5 on the 20 μm cell strainer
prepared in the previous step to separate single cells
from organoids (Fig. 12b). After this passage
organoids should be entrapped in the 20 μm cell
strainer, while single cells should be collected in the
tube.
8. Invert the 20 μm cell strainer on a new 50 mL tube
and wash twice with 5 mL of WM to collect tumor
organoids entrapped inside the 20 μm grid
(Fig. 12c).
9. Discard the 20 μm cell strainer and collect
organoids by centrifuging 5 min at 500×g, T = 8 °C.
10. Remove the supernatant avoiding to disrupt
organoid pellet.
11. If the pellet contains red blood cells (observed as
a red layer on top of the pellet), add 1 mL of
TAC buffer and incubate 10 min in a 37 °C water
bath. Then, neutralize with 10 mL of WM and
centrifuge (5 min at 500×g, T = 8 °C) to collect
organoids.
Fig. 10 Mosaic reconstitution of Transmission Electron Microscopy of a PDO. Scale bar = 5 μm. Images acquired with Tecnai Spirit BT (FEI)
transmission electron microscope, magnification of each single image 2550 ×
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Fig. 11 Transmission Electron Microscopy images of typical specialization and characteristic features in a PDO. In panels a and b it is possible to
appreciate the presence of intracellular granules, while in panels c and d we observe structures similar to intercellular channels. Image acquired
with Tecnai Spirit BT (FEI) transmission electron microscope. Panel a and b magnification 2250×; panel c magnification 20,500× and panel d
magnification 26,500 ×
Fig. 12 Images of the filtration passages to obtain PDO from a surgical specimen. a Filtration throught 100 μm cell strainer. b Entrapment of
organoids on top of a 20 μm cell strainer and c recovery of organoids from the top of a 20 μm cell strainer
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12. If the pellet contains a lot of fat, perform one or
two additional washing step with 10 mL of WM.
13. Remove carefully the supernatant and resuspend
organoid pellet in Matrigel 90% in WM (Corning,
Matrigel Basement Membrane Matrix Growth
Factor Reduced, Phenol Red Free, #356231) for
seeding. Table 1 reports the volume of Matrigel
necessary to seed organoids in plates of different
formats. If the pellet is invisible, we advise to seed
the sample in a well of 24-wells plate.
14. Seed in a pre-warmed multiwell plate, then invert
the plate to avoid organoid sinking. After 10 min,
transfer the seeded plate into the incubator for 20
min, to allow Matrigel solidification.
15. In the meantime, prepare Complete Culture
Medium (CCM) [6]. At the end of the process of
Matrigel solidification, invert the plate, gently add
CCM to organoid-matrigel drops and transfer into
incubator for culturing (refer to Table 2 for volume
of CCM required/plate size).
Protocol #2: Tissue digestion from breast cancer biopsy
Fresh tumor biopsy of about 1.5 mm × 20mm × 1.5 mm
(2 samples obtained from a 12 gauge core needle biopsy)
should be transferred into sterile WM and within 1 h
from collection processed within 1 h from collection in
sterile conditions in a biosafety cabinet (hood) using Bio-
safety Level 2 (BSL2) techniques.
1. Transfer the solid tumor tissue in a 6 cm petri dish
and assure to keep the tissue moist with PBS.
2. Mince the tissue with scalpel by performing a criss
cross motion.
3. Transfer the minced tissue in a pre-weighted 15 mL
tube using a cell lifter.
4. Digest the minced tissue in 2 mL of digestion buffer
(DMEM-F/12 supplemented with 10 mM HEPES,
2% BSA, 0.5 μg/ml hydrocortisone, 50 μg/mL
gentamycin) supplemented with Collagenase III
(Wortington #LS004182; 0.2 mg/mL) and with
Hyaluronidase (Sigma #H3884; 1000 U/mL) for 3–4
h at 37 °C under shaking (200 rpm).
5. To remove undigested fragments and debris, filter
on 100 μm cell strainer and collect the floe-through
sample.
6. Wash the strainer with 5 mL WM.
7. Repeat step 6.
8. Collect organoids by 5 min at 500×g, T = 8 °C
centrifugation.
9. Remove the supernatant avoiding to disrupt organoid
pellet.
10. If the pellet contains red blood cells (observed as a
red layer on top of the pellet), resuspend the pellet
in 1 mL of TAC buffer and incubate 10 min in a
37 °C water bath. Then, neutralize with 10 mL of
WM and centrifuge (5 min at 500×g, T = 8 °C) to
collect organoids.
11. If the pellet contains a lot of fat, perform an
additional washing step with 10 mL of WM.
12. Remove carefully the supernatant and resuspend
organoid pellet in Matrigel 90% in WM (Corning,
Matrigel Basement Membrane Matrix Growth
Factor Reduced, Phenol Red Free, #356231) for
seeding. In Table 1 is reported the volume of
Matrigel necessary to seed organoids in plates of
different formats. If the pellet is invisible, we advise
to seed the sample in a well of 24-wells plate.
13. Seed in a pre-warmed multiwell plate, then invert
the plate to avoid organoid sinking. After 10 min,
transfer the seeded plate into the incubator for 20
min, to allow Matrigel solidification.
14. In the meantime, prepare CCM. At the end of the
process of Matrigel solidification, gently add CCM
to organoid-matrigel drops and transfer the plate
back to the incubator for culturing (refer to Table 2
for CCM volume required/plate size).
Protocol #3: PDO culturing
Once seeded in matrigel droplets, generally, Breast Can-
cer organoids should be passed every 2 weeks to prevent
that they become too much (a) or too big (b). Two dif-
ferent procedures should be performed in each case.
The procedure (a) should be followed when density in
Matrigel drop is high but organoids are small (Fig. 13);
the protocol (b) should be performed when organoids
are big while not necessary too crowded (Fig. 14). An ex-
ample of organoids growth rate is shown in Fig. 15.
a) Organoid expansion
Table 1 The volume of 90% Matrigel necessary to resuspend
PDO before seeding in different plate format, established as μL
/well
Plate format μL of 90% Matrigel/well
6-wells 150 μL
12-wells 70 μL
24-wells 35 μL
Table 2 Summarizes the the volume of CCM required for each
type of well
Plate format mL of CCM/well
6-wells 1.5–2 mL
12-wells 1 mL
24-wells 0.5 mL
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1. Using CCM remained in the plate, dissolve the
Matrigel drop and transfer the medium containing
Matrigel and organoids in a new 15 mL tube.
2. Wash twice the plate using fresh WM (at least 2
mL to wash a well of 6 multiwell plate)
3. Collect washes and centrifuge 5min at 500×g, T = 8 °C.
4. Discard the supernatant.
5. Resuspend in the appropriate amount of 90%
Matrigel to expand the culture 1:2–1:3.
6. Seed organoids-matrigel drops and invert the plate
to avoid organoid sinking.
7. After 10 min, transfer the seeded plate into the
incubator for 20 min, to allow Matrigel
solidification.
8. In the meantime, prepare Complete CCM.
9. At the end of the process of Matrigel solidification,
gently add CCM to organoid-matrigel drops and
transfer into incubator for culturing (Fig. 13).
b) Organoid shearing
PDO from breast cancer are generally compact orga-
noids, therefore we suggest to follow the procedure de-
scribed below. Instead, in case of grape-like or non
compact organoids, avoid the use of TrypLE and divide
PDO by mechanical shearing only.
1. Using CCM remained in the plate, dissolve
the Matrigel drop and transfer the medium
containing Matrigel and organoids in a new
15 mL tube.
2. Wash twice the plate using fresh WM (at least 2
mL to wash a well of 6 multiwell plate)
3. Collect washes and centrifuge 5min at 500×g, T = 8 °C.
4. Discard the supernatant leaving 1 mL of WM.
5. Add 1mL of TrypLE to obtain a WM:TrypLE ratio
of 1:1
6. Using a flamed glass Pasteur, pipette up-and down for
20 times organoid suspension to combine enzymatic
shearing of TrypLE with mechanical shearing.
7. Check shearing process under the light microscope.
If there aren’t signs of organoid rupture continue
mechanic shearing pipetting up and down 10–15
times more.
8. Neutralize TrypLE with 10 mL of WM and
centrifuge to collect sheared organoids.
9. Discard the supernatant and resuspend organoids in
the appropriate amount of 90% Matrigel to expand
the culture 1:2–1:3.
10. Seed organoids-matrigel drops and invert the plate
to avoid organoid sinking.
11. After 10 min, transfer the seeded plate into the
incubator for 20 min, to allow Matrigel
solidification.
12. In the meantime, prepare CCM.
13. At the end of the process of Matrigel solidification,
gently add CCM to organoid-matrigel drops and
transfer into incubator for culturing (Fig. 14).
Fig. 13 Images of PDO culture before and after expansion
Fig. 14 Images of PDO culture before and after the shearing process
Fig. 15 Schematic growth rate profile of three representative
PDO cultures
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Protocol #4: PDO paraffin embedding for
immunohistochemistry and histology
1. Remove CCM from the selected plate.
2. To easily visualize and manipulate PDO drop label
it by 30 min incubation with 0.05% crystal violet.
3. At the end of incubation wash PDO thrice with
PBS to remove the excess of crystal violet (Fig. 16).
4. At the same time, dissolve agarose in milliQ water
boiling the mixture to obtain a suspension of 2%
agarose.
5. Remove a labelled drop of PDO with a cell lifter
from the multi well plate and place it in a 15 × 15 ×
5mm mold pre-filled with unsolidified agarose 2%.
6. Place inside the agarose matrix about 3–4 Matrigel
drops of PDO.
7. Wait about 15 min to obtain complete solidification
of 2% agarose matrix (Fig. 16).
8. Remove the agarose piece from the mold and place
it in a histological cassette in an oriented way
(Fig. 16).
9. Put the histological cassette in 10% buffered
formalin for fixation (Fig. 16).
10. Fixation and paraffin embedding have been
performed using histo star embedding workstation
(ASP300 Leica). After 2 h of incubation in buffered
Formalin 10%, the sample was dehydrated with 3
cycles of 1 h and one of 2 h in 95% ethanol,
followed by 2 cycles of 1 h and one of 2 h in
absolute ethanol. Then, the sample was subjected to
2 cycles of incubation in Bioclear (Bio-Optica) for 1
h each, followed by one cycle lasting 2 h. After that,
the sample was included in paraffin wax. Inclusion
has been performed by two cycle of 1 h followed by
one of 2 h.
11. Cut paraffin-embedded PDO in histological slides of
3,5 μm and labelled with VENTANA, Bench Mark
ULTRA following automatized standard protocols
established for E-caderin, c-ErbB2, estrogen recep-
tor, progesterone receptor and Ki67 immunohisto-
chemistry (ICH). Clones of antibodies used for
immunohistochemistry are reported in Table 3.
12. At the end of ICH procedure, counter stain
histological slides with eosin, dehydrate with ethanol
(2 cycles in 95% ethanol and 2 cycles in
100% ethanol) and Bioclear and mount with a
coverslip.
Protocol #5: PDO processing for TEM imaging
1. Remove a drop of PDO embedded in 90% Matrigel
with a cell lifter from a multi well plate and place it
in a 1.5 mL tube.
2. Add 1 mL of 2.5% glutaraldehyde in cacodylate
buffer overnight.
3. Wash thrice with cacodylate buffer.
4. Fix with osmium tetroxide 1.5% in cacodylate buffer
for 2 h.
5. Wash again with cacodylate buffer.
6. Dehydrate with an ascending ladder of ethanol
from 50 to 100%.
7. Include in epon.
8. Cut slides of 70–80 nm and label them with uranil
acetate and lead citrate.
9. Acquire images with the Transmission Electron
Microscope Tecnai Spirit BT FEI.
Protocol #6: PDO freezing
Once obtained a 6 well plate full of organoids ranging
from 40 to 100 μm, we could proceed to freezing. 2–3 days
before freezing, one should share them in order to obtain
a pool of dense and homogeneously small organoids.
Fig. 16 Images of main steps to manage PDO to obtain Formalin-Fixed and Paraffin Embedded sample. The procedure to prepare PDO for
paraffin embedding could be summarized into 3 main steps: 1) crystal violet stain; 2) agarose embedding and 3) formalin fixation after the
placement of the agarose cube containing PDOs in the histological box
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1. Using CCM remained in the plate, dissolve the
Matrigel drop and transfer the medium containing
Matrigel and organoids in a new 15 mL tube.
2. Wash twice the plate using fresh WM (at least 2
mL to wash a well of 6 multiwell plate)
3. Collect washes and centrifuge 5 min at 500×g, T =
8 °C.
4. Discard the supernatant leaving 1 mL of WM.
5. Add 1mL of TrypLE to obtain a WM:TrypLE ratio
of 1:1.
6. Using a flamed glass Pasteur, pipette up-and down
for 20 times organoid suspension to combine en-
zymatic shearing of TrypLE with mechanic
shearing.
7. Check shearing process under the light microscope.
If there aren’t signs of organoid rupture continue
mechanic shearing pipetting up and down 10–15
times more.
8. Neutralize TrypLE with 10 mL of WM and
centrifuge to collect sheared organoids.
9. Discard the supernatant and resuspend organoids in
the appropriate amount of 90% Matrigel to re-seed
them in a 6 multiwell plate.
10. Seed organoids-matrigel drops and invert the plate
to avoid organoid sinking.
11. After 10 min, transfer the seeded plate into the
incubator for 20 min, to allow Matrigel
solidification.
12. In the meantime, prepare Complete Culture
Medium (CCM).
13. After Matrigel solidification, gently add CCM to
organoid-matrigel drops and transfer the plate into
the incubator for culturing.
14. After a couple of day collect organoids using CCM
in the plate to dissolve the Matrigel drop and
transfer the medium containing Matrigel and
organoids in a new pre-chilled 15 mL tube. Use two
15mL tubes to collect organoids from a full 6 mul-
tiwell plate.
15. Leave the tube on ice and wash twice the plate
using Ice-cooled WM (at least 2 mL to wash a well
of 6 multiwell plate)
16. Collect washes and centrifuge 5 min at 500×g, T =
8 °C.
17. Discard the supernatant leaving 1 mL of WM.
18. Add 11 mL of ice-cooled WM and incubate 10 min
in ice. This incubation should help in dissolve
Matrigel.
19. Leaving tubes in ice, pipet up and down and
centrifuge 5 min at 500×g, T = 8 °C.
20. Discard the supernatant and repeat the washing
18–20 if the suspension of Matrigel and organoids
is more than 0.2 mL.
21. Leave the tubes in ice and add 3 mL of freezing
medium in each 15 mL tube.
22. Prepare 6 aliquots of PDO suspension from each
15mL tube by pipetting 0.5 mL of PDO suspension
into each cryovial.
23. Immediately transfer cryovials in a Nalgene
cryostep for 24 h at − 80 °C, then store the aliquots
in liquid nitrogen for long term conservation.
Protocol #7: PDO thawing
The day before the thawing of an organoid vial it is ne-
cessary to pre-warm a 24-well tissue culture plate in the
incubator.
1. Pre-warm WM at 37 °C before use.
2. Thaw the vial rapidly by soaking in a 37 °C water
bath under agitation until there is a piece of frozen
material left.
3. Remove the vial from the water bath and clean it
with ethanol before the transfer in a biosafety hood.
4. Transfer the thawed organoids to a sterile 15 ml
falcon tube and add 1 ml of warm WM drop by
drop while shaking the bottom of the tube.
5. Mix carefully by pipetting up and down a few times
to dilute the freezing medium and slowly add 9 mL
of warm WM into the 15 mL tube containing the
organoids.
6. Invert the tube a few times.
7. Centrifuge 5 min at 500×g, T = 8 °C
8. Discard the supernatant without disrupting the
pellet and resuspend the pellet in the same volume
of 90% matrigel that was frozen in the vial (about
70 μL).
9. Seed crowded in a pre-warmed 24-multiwell plate
to support organoids recovery from thawing
procedure.
10. Invert the plate to avoid organoid sinking.
Table 3 Summarizes the antibodies used for ICH with VENTANA
Target Commercial name clone Product code
c-erbB2 PATHWAY anti-HER2/neu 4B5 Rabbit Mab 05278368001
E-caderin E-caderin EP700Y Rabbit Mab 05973872001
Ki67 CONFIRM anti-Ki67 30–9 Rabbit Mab 05278384001
Estrogen Receptor CONFIRM anti-ER SP1 Rabbit Mab 05278406001
Progesteron Receptor CONFIRM anti-ER 1E2 Rabbit Mab 05277990001
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11. After 10 min, transfer the seeded plate into the
incubator for 20 min, to allow Matrigel
solidification.
12. In the meantime, prepare CCM.
13. After Matrigel solidification, gently add CCM to
organoid-matrigel drops and transfer into incubator
for culturing.
14. Follow organoids growth for some day to verify that
the freezing/thawing process has been placed
correctly.
Materials
Human breast primary tumor tissue from surgical speci-
men or from biopsy (fresh; the quantity usually varies).
Ice
6 cm Ø Petri dish, sterile (Euroclone, #ET2060).
10 cm Ø Petri dish, sterile (Euroclone, #ET2100).
Nalgene Cryo 1 °C freezing container filled with iso-
propanol (Nalgene #5100–0001).
50 mL conical tubes, sterile (Euroclone, #ET5050B).
15 mL conical tubes, sterile (Euroclone, #ET5015B).
2 mL cryovial tubes, sterile (Euroclone, #ECC3112SS).
24-well standard tissue culture plate (Euroclone,
#ET3024).
12-well standard tissue culture plate (Euroclone,
#ET3012).
6-well standard tissue culture plate (Euroclone,
ET#3006).
Disposable scalpels (#10 blades), razor blades, sterile.
Disposable cell lifter (Fisher #08–100-240), sterile.
Cell strainer (100 μm, Pluristrainer, #43–50,100-51),
sterile.
Cell strainer (20 μm, Pluristrainer, #43–50,020-03),
sterile.
Parafilm M.
5 mL tips (Euroclone, #EPS05N).
10 mL tips (Euroclone, #EPS10N).
P1000 low retention filter tips (ClearLine,#713,119).
P200 low retention filter tips (ClearLine, #713131).
P10 tips (Sorenson, Multifit pipette tips,#1,710,010,238).
P1000 filter tips (Gilson, #DF1200ST).
Moulds 15 × 15 × 5mm (Simport Scientific, #M475–2).
Equipment
37 °C shaker (GFL).
Refrigerated centrifuge (Thermo Scientific, Megafuge
16R).
0.5% CO2 incubator (Thermo Scientific, Heracell
150i).
Biosafety 2 cabinet (Thermo Scientific, Herasafe KS).
Warm bath (MPM instruments, M418-BM).
Gilson Pipette p1000, p200, p20 and p10.
Media and Buffers
Digestion Buffer Hyclone DMEM-F/12 1:1 (Thermo
Scientific #SH30023.01) supplemented with:
10 mM HEPES (Sigma-Aldrich; #H3885),
2% BSA (Sigma-Aldrich; #A7906),
0.5 μg/mL hydrocortisone (Sigma-Aldrich; #H0135),
10 μg/mL gentamycin (Euroclone #ECM0011B; 10 mg/
mL).
WM Medium Hyclone DMEM-F/12 1:1 (Thermo Sci-
entific #SH30023.01) supplemented with:
10 mM HEPES (Sigma-Aldrich; #H3885),
10 μg/mL gentamycin (Euroclone #ECM0011B; 10 mg/
mL),
2 mM L- Glutamine (Euroclone ECB3000D-20; 200
mM),
1% Pennicilin/streptomycin (Euroclone #ECB3001D,
100×),
2.5 μg/mL Amphotericin B (Euroclone #ECM00 09D;
250 μg/mL).
TAC Buffer 1:9 of 170 mM Tris, pH 7.4 and 150 mM
NH4Cl, pH 7.4.
CC Medium [6] Hyclone DMEM-F/12 1:1 (Thermo Sci-
entific #SH30023.01) supplemented with:
10 mM HEPES (Sigma-Aldrich; #H3885),
10 μg/mL Gentamycin (Euroclone #ECM0011B; 10
mg/mL),
2 mM L- Glutamine (Euroclone ECB3000D-20; 200
mM),
1% Pennicilin/streptomycin (Euroclone #ECB3001D,
100×),
2.5 μg/mL Amphotericin B (Euroclone #ECM00 09D;
250 μg/mL),
5 mM Nicotinammide (Sigma-Aldrich, #N0636, 250
mM).
1.25 mMN-acetylcysteine (Sigma-Aldrich, # A9165,
125 mM).
1× B27 supplement (Gibco, #17504–44, 50×).
250 ng/mL R-spondin 3 (R&D, #3500-RS/CF, 25 μg/
mL)*.
5 nM Heregulin (Peprotech, #100–03, 7.14 μM)*.
5 ng/mL KGF (Peprotech, #100–19, 10 μg/mL)*.
20 ng/mL FGF10 (Peprotech, #100–26, 25 μg/mL)*.
5 ng/mL EGF (Peprotech, #AF-100-15, 5 μg/mL)*.
100 ng/mL Noggin (Peprotech, #120-10C, 20 μg/mL)*.
500 nM A83–01 (Tocris, #2939, 500 μM)*,**.
5 μM Y-27632 (Abmole,#M1817, 5 mM)*.
500 nM SB202190 (Sigma-Aldrich, #S7067, 500 μM)*.
* Add fresh the day of use.
** dissolve in DMSO.
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Cacodylate Buffer 0.05M pH 7.2 Prepare 100 mL of a
0.2M stock solution of sodium cacodylate in milli Q
water (4.28 g/100ml). Then, add 8.4 mL of 0.2M HCl to
100 mL of cacodylate stock solution, followed by the
addition of milli Q water to a final volume of 400 mL.
The resulting Cacodylate buffer display a molarity of
0.05 and a pH of 7.2.
Reagents
Collagenase enzyme stock (10×) Collagenase III (Wor-
tington #LS004182; 2 mg/mL).
Hyaluronidase enzyme stock (100×) Hyaluronidase
(Sigma #H3884; 100,000 U/mL).
70% ethanol.
TrypLE Select (Gibco #12563–029; 1×).
Matrigel Growth Factor Reduced Basement Membrane
Matrix Phenol-red free (Corning #356231).
Agarose (Sigma-Aldrich, #A9539).
DMSO (Sigma-Aldrich, #D2650).
Abbreviations
CCM: Complete culture Medium; ICH: Immunohistochemistry; PDO: Patient
Derived Organoid; PDX: Patient Derived Xenograft; WM: Working Medium
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